John Crowley

John Francis Crowley was the founder of Orexigen Therapeutics, Inc., founded in 2003, where the title held was President & Chief Executive Officer from 2003 to 2005.
Mr. Crowley was the founder of Novazyme Pharmaceuticals, Inc., founded in 2000, where the title held was President & Chief Executive Officer from 2000 to 2002.
Mr. Crowley was the founder of Amicus Therapeutics, Inc., founded in 2002, where the title held was Executive Chairman from 2022 to 2024.
Current jobs include President & Chief Executive Officer at Biotechnology Innovation Organization starting in 2024, Director at St. Peter's University Hospital, Director at Global Genes, Member-Science & Technology Council at the University of Notre Dame, Co-President at Scioderm, Inc. since 2013, and Member of The Wall Street Journal CEO Council.
Former jobs include National Chairman at Make-A-Wish Foundation of America from 2009 to 2016, Director-Business Strategy at Bristol Myers Squibb Co. from 1998 to 2000, Independent Director at Intellia Therapeutics, Inc. from 2020 to 2023, Independent Director at Entrada Therapeutics, Inc. from 2019 to 2023, Litigation Associate-Health Care Practice Group at Bingham Summers Welsh & Spilman, Senior Vice President at Genzyme Therapeutics Ltd. from 2001 to 2003, and Trustee at BioNJ, Inc. Education includes an undergraduate degree from Georgetown University conferred in 1992, an MBA from Harvard Business School, and a graduate degree from the University of Notre Dame The Law School.